<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188824</url>
  </required_header>
  <id_info>
    <org_study_id>DMR99-IRB-137</org_study_id>
    <nct_id>NCT01188824</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)</brief_title>
  <official_title>The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shin Kong Wu Ho-Su Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cathay General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>En Chu Kong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuang Tien General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the Safety and Efficacy of Cilostazol in slowing
      down the progression of peripheral arterial disease (PAD) in ischemic stroke patients with
      PAD in Taiwan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One thousand patients will be randomized to take cilostazol (500 patients) or placebo (500
      patients) in parallel groups. Patients will be screened and evaluated on Visits 1 to assess
      their eligibility prior to randomization. The treatment period (Visit 1-6) will last 12
      months and the patient will receive initial and follow-up evaluation (section 4.5) including
      history and physical examinations, and baseline and end of treatment ABI and carotid IMT
      assessments. Vascular events and death as well as adverse events including bleeding
      complications will also be recorded at intervals as detailed in section 4.5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for this study is slowdown of PAD progression based on ABI.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid intima-media thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Carotid intima-media thickness.
Vascular events, including recurrent stroke, myocardial infarction, unstable angina,other vascular events, and all death.
Safety, including major bleeding events, hemorrhagic stroke, any death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pletaal® (Cilostazol) 100 mg, bid p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo
1 tablet, bid p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>100 mg, bid p.o.</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 tablet, bid</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, age ≧50 years; for female patients, postmenopausal (defined
             as at least 2 years without menses) has to be confirmed.

          -  Ischemic stroke or transient ischemic attack patients who have been taking aspirin 100
             mg, QD

          -  Neurologically and clinically stable at inclusion

          -  PAD (i.e. ankle-brachial index or ABI &lt;1.0)

        Exclusion Criteria:

          -  Patients unable to give informed consent

          -  Patients with history of any type of hemorrhagic stroke (intracerebral
             hemorrhage,subarachnoid hemorrhage, or others)

          -  Modified Rankin Scale &gt;4

          -  Patients with history of dementia requiring institutional care

          -  Known brain tumor

          -  Known anemia (defined as hemoglobin &lt;10.0 g/dL)

          -  Known thrombocytopenia (defined as platelet count below 100,000/cm3)

          -  AST or ALT &gt; 3 x Upper Normal Limit

          -  Calculated creatinine clearance &lt; 30 ml/min according to the Copckroft formula)

          -  Known hemostasis or coagulation disorder

          -  Congestive heart failure, defined as a previous definitive diagnosis, or present
             symptoms of at least Category II of the NYHA classification system for CHF

          -  Revascularization of the lower limb arteries including bypass surgery, endovascular
             procedures

          -  Symptomatic PAD requiring treatment with cilostazol

          -  Known stenosis of the upper limb arteries that may affect the documentation of ABI

          -  Patients with known hypersensitivity to cilostazol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Y. Hsu, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

